Samsung Biologics Shares Rally on Strong Growth: Key Insights Samsung Biologics stays a Buy: despite labor, legal, and quality recall risks, 2026.03 revenue rose 25.8% YoY and operating profit 35.0% YoY, supporting margin resilience and upside. 2026년 06월 02일 English
